Skip to main content
Pierluigi Porcu, MD, Oncology, Philadelphia, PA

PierluigiPorcuMD

Oncology Philadelphia, PA

Hematologic Oncology

Professor of Medical Oncology, Division Director of Hematologic Malignancies, and IRT Program Leader, Sidney Kimmel Cancer Center at Jefferson

Dr. Porcu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Porcu's full profile

Already have an account?

  • Office

    925 Chestnut St
    Ste 420A
    Philadelphia, PA 19107
    Phone+1 215-955-8874
    Fax+1 215-955-2340

Summary

  • Dr. Pierluigi Porcu is a medical oncologist and physician scientist with a research focus in T-cell and NK-cell lymphoma and EBV-associated lymphomas. He is Division Director, Heme Malignancies and Hematopoietic Stem Cell transplantation and Program Leader, Immune Cell Regulation and Targeting at the Sidney Kimmel Cancer Center at Thomas Jefferson University, in Philadelphia, PA. He received his medical degree from University of Torino Faculty of Medicine and has been in academic practice in the US more than 20 years. He specializes in T-cell and NK-cell lymphomas and is an expert in the development of new therapies for blood cancers.
  • 2013 ASH - Interview with Pierluigi Porcu, MD - Former CLF Board Member

    Interview with with former CLF Board Member Pierluigi Porcu, MD, OSU Comprehensive Cancer Center.

    Meet Team Buckeye: PG Porcu, MD

    Associate Professor PG Porcu, MD, rides in Pelotonia for his patients. Hear why he thinks Pelotonia is such an important experience. 100% of all funds raised by

    2015 Detroit PEF - Q&A with Clinician Panel

    The question and answer session with our guest clinicians recorded at our Patient Educational Forum held in Detroit, Michigan.

    Cutaneous Lymphomas: Diagnosis and Staging

    Overview of how cutaneous lymphoma is diagnosed and classified; plus an explanation of staging.

    Dr. Porcu Discusses CTCL

    Pierluigi Porcu, MD, associate professor of internal medicine, Division of Hematology, Department of Internal Medicine, Wexner Medical Center, The Ohio State Un

    ASH 2013 - PierLuigi Porcu, M.D., and the Cutaneous Lymphoma Foundation.

    From ASH 2013, PierLuigi Porcu, M.D., discusses the Cutaneous Lymphoma Foundation's commitment to funding promising research with it's CLARIONS research awards

    Debate: What is the best approach for relapsed T cell lymphoma? - AlloSCT

    The continued evolution and refinement of strategies for disease diagnosis, risk assessment, therapeutic intervention and disease management have provided patie

Education & Training

  • Indiana University School of Medicine
    Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 1996 - 1999
  • Indiana University School of Medicine
    Indiana University School of MedicineResidency, Internal Medicine, 1993 - 1996
  • University of Torino Faculty of Medicine
    University of Torino Faculty of MedicineClass of 1987

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 2019 - 2025
  • PA State Medical License
    PA State Medical License 2016 - 2024
  • OH State Medical License
    OH State Medical License 1999 - 2018

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2009-2014
  • America's Top Doctors for Cancer Castle Connolly, 2007-2013
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Quality of Life in Cutaneous T Cell Lymphoma Patients Treated with the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat: Results from MAVORIC  
    Pierluigi Porcu, MD, European Journal of Cancer
  • Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 Study  
    Michael S Khodadoust, Pierluigi Porcu, Francine Foss, Andrei R Shustov, Satish Shanbhag, Lubomir Sokol, Steven M Horwitz, Elad Sharon, European Journal of Cancer
  • IPH4102 in relapsed/refractory Cutaneous T Cell Lymphoma (CTCL): Results of the First-in-Human Multicenter Phase 1 Study  
    Pierluigi Porcu, Basem William, Michael Khodadoust, European Journal of Cancer

Abstracts/Posters

  • Reversible DNA Hypermethylation of the Interleukin-15 (IL-15) Promoter Induces IL-15 Expression, Drives the Pathogenesis of T-Cell Large Granular Lymphocytic Leukemia ...
    Pierluigi Porcu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • A Prospective Cohort of Black Patients with Mycosis Fungoides and S_zary Syndrome: Subset Analysis of the Mavoric Trial
    Pierluigi Porcu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • A phase Ib/II study of oral nanatinostat (N) and valganciclovir (VG) in subjects with Epstein-Barr virus (EBV)-associated lymphomas. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Efficacy of Mogamulizumab By Prior Systemic Therapy in Patients with Previously Treated Cutaneous T-Cell Lymphoma: Post Hoc Analysis from the Phase 3 Mavoric Study 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Long-Term Efficacy and Safety from the Copanlisib CHRONOS- Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Authored Content

  • SOHO 2021: A Rapidly Changing Treatment Landscape in Classical Hodgkin’s LymphomaSeptember 2021
  • Quality of Life in Cutaneous T Cell Lymphoma Patients Treated with the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat: Results from MAVORICAugust 2018
  • IPH4102 in relapsed/refractory Cutaneous T Cell Lymphoma (CTCL): Results of the First-in-Human Multicenter Phase 1 StudyAugust 2018
  • Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 StudyAugust 2018
  • Join now to see all

Press Mentions

  • Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of Its Recent End of Phase 2 Meeting with the FDA
    Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of Its Recent End of Phase 2 Meeting with the FDADecember 7th, 2020
  • Viracta Announces Oral Presentation on Lead Program for EBV-Associated Lymphomas at the 2019 American Society of Hematology (ASH) Annual Meeting
    Viracta Announces Oral Presentation on Lead Program for EBV-Associated Lymphomas at the 2019 American Society of Hematology (ASH) Annual MeetingNovember 6th, 2019
  • Treatment Delays with CAR-T Therapy: A High Price to Pay
    Treatment Delays with CAR-T Therapy: A High Price to PaySeptember 11th, 2019
  • Join now to see all

Professional Memberships

Other Languages

  • Italian